MST1R and lung carcinoma: For example, the dual MET/MST1R (RON) kinase inhibitor, LY2801653 which is a type-II ATP competitive, slow-off inhibitor binding to the kinase domains of these RTKs, decreased tumor growth and angiogenesis in the lung cancer setting and demonstrated greater efficacy than crizotinib (28).